Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091506 | 0.85 | NPC1 (0.40) | TDP1TP53 | |
| SCHEMBL3084411 | 0.85 | LMNA (0.31) | TP53 | |
| SCHEMBL3094887 | 0.81 | VKORC1 (0.36) | TP53 | |
| SCHEMBL3078552 | 0.81 | LTA4H (0.41) | TDP1 | |
| SCHEMBL9589093 | 0.75 | CA12 (0.33) | — | |
| SCHEMBL3090097 | 0.73 | RAB9A (0.37) | HTR1DHTR1BTDP1IDO1 | |
| SCHEMBL3078133 | 0.73 | HTR1D (0.37) | HTR1DHTR1BTDP1IDO1TP53 | |
| SCHEMBL9590317 | 0.72 | FAAH (0.32) | — | |
| SCHEMBL9588423 | 0.71 | — | — | |
| SCHEMBL3074353 | 0.69 | SLC5A2 (0.34) | HTR1DHTR1BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207134-B2 | Fused ring spiroketal derivative and use thereof as anti-diabetic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | REN, WNK1, GCKR | HTR1D 3370/4885HTR1B 4065/4885TDP1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.